Navigation Links
Can Cannabidiol (CBD) Fight Metastatic Cancer? According to the latest research the answer is yes.

SAN DIEGO, Sept. 21, 2012 /PRNewswire/ -- Medical Marijuana Inc. (OTC: MJNA), a leading hemp industry innovator, is pleased to report on a September 18 San Francisco Chronicle Article, "Pot compound seen as tool against cancer."

The article states that scientists at California Pacific Medical Center who have been researching marijuana's compounds for the 20 years have found that Cannabidiol, or CBD, has the ability to "turn off" the DNA that causes "breast and other types of cancers" to metastasize. CBD is the second-most abundant cannabinoid within marijuana, but does not cause the psychotropic high of THC.

As stated in the article: "We started by researching breast cancer," said scientist Pierre Desprez. "But now we've found that Cannabidiol works with many kinds of aggressive cancers--brain, prostate--any kind in which these high levels of ID-1 are present."

Desprez said he is hopeful clinical trials will begin immediately. He currently has grant funding through the National Institutes of Health, Susan G. Komen for the Cure, the U.S. Department of Defense and the California Breast Cancer Research Program.

As previously announced in the MJNA press release dated September 5, MJNA portfolio company, Red Dice Holdings, recently launched its Hemp-based high concentrate CBD health and wellness products, Dixie X, for over-the-counter sales. These Cannabidiol products represent the highest strength of CBD products on the market today, and this same concentrate will soon be used to launch the CanChew Biotechnologies line of CBD-enriched chewing gum. Click here for recent production news from PhytoSphere. Dixie X can currently be purchased in over 100 retail locations in Colorado, Arizona and New Mexico as well as on-line by anyone living in the U.S. at

In short, MJNA and its portfolio company, PhytoSphere Systems, currently produces non-THC, high quality CBD enriched Hemp oil that according to this story, may fight the most aggressive forms of cancers we know of today.

Studies, such as those in this article and at Project CBD, have continually shown that these non-psychoactive CBD wellness products provide powerful relief for pain and anxiety sufferers, but without the euphoric effects provided by THC. The CBD health and wellness industry is estimated by MJNA to be a $5 billion market.

While the company cannot make medical claims, the Dixie X product line has been extremely well received by consumers with many positive testimonials received since launch. Please Click here for customer testimonials:

According to the Chronicle article, when scientists first exposed metastatic cancer cells to Cannabidiol in a petri dish, "the cells not only stopped acting crazy but they also started to revert to a normal state. Both scientists were shocked…But they got the same results each time they did it."

"This article and the findings it reports just confirm what many have known, that Cannabidiol or CBD have tremendous health and wellness potential. We are pleased that our Dixie X line of products are available right now to patients who have an immediate need for CBD and are searching for an easy way to find it," states Ted Caligiuri, Interim President of MJNA. "We take great pride in knowing that our Dixie X line may be of significant health benefit to not only all cancer patients, but those in late stages of metastatic disease. We are also looking forward to the clinical trials that will soon be underway and thank the National Institute of Health, Susan G. Komen Foundation and others for their unwavering commitment to funding this necessary research."

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value.

Medical Marijuana Inc. does not grow, sell or distribute any substances that violate United States Law or the controlled substance act.

For more information, please visit the company's website at:


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

These statements have not been evaluated by the Food and Drug Administration (FDA). These products and statements are not intended to diagnose, treat, cure, or prevent any disease.

Corporate Contact:

Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)

Investor Relations Contact:

Stuart T. Smith
SmallCapVoice.Com, Inc.
P. 512-267-2430
F. 512-267-2530
AIM: SmallCapVoice7

SOURCE Medical Marijuana Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sabiya Donates Odor-Fighting Athletic Apparel to the Corps of Exploration Aboard E/V Nautilus
2. Bed Bugs Bite on Businesses, Green Bean Buddy Advises Owners to Fight Back With a Non-Toxic Bed Bug Bully Product
3. Nanosurgery and the fight against cancer: Major breakthrough at Polytechnique Montral
4. MU researchers identify key plant immune response in fight against bacteria
5. Synteract and MediciNova Partner in "Fight For Air Walk" to Support the American Lung Association in California
6. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
7. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
8. Life Sciences Venture Capital Funding Shrinks for Fourth Straight Quarter According to the MoneyTree Report
9. Van Andel Institute Research Symposium Showcases Latest Developments In Parkinsons Research
10. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
11. San Diego Medical Director Wins Two Book Awards For Latest Medical Thriller
Post Your Comments:
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper ... unless it is bound to proteins, copper is also toxic to cells. With ... Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in the ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:11/17/2015)... PARIS , November 17, 2015 ... November 2015.   --> Paris from ... --> DERMALOG, the biometrics innovation leader, has invented the ... and fingerprints on the same scanning surface. Until now two ... fingerprints. Now one scanner can capture both on the same ...
(Date:11/12/2015)... -- A golden retriever that stayed healthy despite having the ... a new lead for treating this muscle-wasting disorder, report ... MIT and Harvard and the University of São Paolo ... Cell, pinpoints a protective gene that boosts muscle ... Boston Children,s lab of Lou Kunkel , PhD, ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
Breaking Biology News(10 mins):